Scott Gottlieb

Director at Illumina

Dr. Gottlieb is currently a special partner at the venture capital firm New Enterprise Associates (NEA) and a resident fellow at the American Enterprise Institute (AEI). From 2017 to 2019, he served as the 23rd commissioner of the Food and Drug Administration (FDA).

During his time at the FDA, Dr. Gottlieb helped make the regulatory process for the development and review of novel drug and medical devices more efficient, including the approval of the first gene-therapy-based cancer treatments. He advanced the FDA’s Oncology Center for Excellence and helped implement the 21st Century Cures Act to accelerate medical product development. He also presided over a record number of approvals for generic and new drugs and novel medical devices, and advanced other efforts to promote food safety, vaccinations, reduce smoking rates, and address opioid addiction.

Dr. Gottlieb previously served as the agency’s deputy commissioner for medical and scientific affairs, and as a senior adviser for medical technology to the FDA Commissioner. He also served as senior policy adviser to the administrator at the Centers for Medicare & Medicaid Services. Prior to joining the FDA as commissioner, he was a clinical assistant professor at New York University School of Medicine. Earlier, he was a practicing physician and hospitalist concurrently with his AEI work.

Timeline

  • Director

    Current role